Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2016-03-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2016-03-18 Chinese
2015年年度报告
Annual Report Classification · 100% confidence The document is titled "2015 年年度报告全文" which translates to "2015 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, business overview, governance, and financial statements. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes comprehensive financial figures, management commentary, and detailed disclosures consistent with an official annual report. Therefore, this document is classified as an Annual Report (10-K). FY 2015
2016-03-18 Chinese
国信证券股份有限公司关于公司2015年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Guosen Securities regarding the 2015 annual use and storage of raised funds by Guangdong Taicheng Pharmaceutical Co., Ltd. It includes specifics on the amount raised, usage, changes in project funding, compliance with regulatory requirements, and an auditor's verification report. The document is focused on the annual review of the use of funds raised through a public offering, including compliance with relevant securities regulations and stock exchange rules. It is not a full annual report (10-K), nor an earnings release or management discussion. It is a specialized audit/verification report on the use of raised capital funds, which fits the category of Audit Report / Information (AR). The document length (6797 characters) and content confirm it is a substantive report, not just an announcement or certification letter, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2015
2016-03-18 Chinese
2015年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制自我评价报告" which translates to "Internal Control Self-Evaluation Report" for the fiscal year ending December 31, 2015. It details the company's internal control evaluation, including governance structure, organizational structure, internal audit, human resources policies, procurement, asset management, production quality, sales management, subsidiary management, related party transactions, external guarantees, fundraising fund management, external investments, and information disclosure. The document includes detailed descriptions of internal control defect standards and their classification into major, important, and general defects for both financial and non-financial reporting. It concludes with a statement that no major defects were found. The document is comprehensive, contains substantive content about internal controls, and is not merely an announcement or certification. It is a standalone report on internal control evaluation, which fits the definition of an Audit Report / Information (AR) as it relates to internal control evaluation results and applied standards, distinct from a full Annual Report (10-K). The document length (7434 characters) supports it being a full report rather than a brief announcement. FY 2015
2016-03-18 Chinese
关于公司募集资金年度存放与实际使用情况的鉴证报告
Regulatory Filings
2016-03-18 Chinese
2015年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '2015 年年度报告摘要' which translates to '2015 Annual Report Summary'. It contains detailed financial data for the year 2015, including revenue, net profit, quarterly financial data, shareholder information, business overview, management discussion and analysis, and notes on accounting policies and changes in consolidated subsidiaries. The document is approximately 7,930 characters long, which is substantial and contains actual financial data and analysis rather than just an announcement or a brief summary. It is clearly a financial report covering the full fiscal year 2015. Therefore, this document fits the definition of an Annual Report (10-K) rather than a summary announcement or other filing types. FY 2015
2016-03-18 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.